Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 1/20 | 1.00 |
| ▸ | MMP12 | P39900 | 1/20 | 1.00 |
| ▸ | MMP13 | P45452 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16511763 | 1.00 | SLC6A2 (1.00) | SLC6A2MMP12MMP13 | |
| SCHEMBL16511332 | 0.92 | SLC6A2 (0.85) | SLC6A2MMP12MMP13 | |
| SCHEMBL16512859 | 0.91 | SLC6A2 (0.83) | SLC6A2MMP12MMP13 | |
| SCHEMBL16512677 | 0.90 | SLC6A2 (0.81) | SLC6A2MMP12MMP13 | |
| SCHEMBL17435767 | 0.89 | SLC6A2 (0.81) | SLC6A2MMP12MMP13 | |
| SCHEMBL12071 | 0.89 | SLC6A2 (0.81) | SLC6A2MMP12MMP13 | |
| SCHEMBL17435717 | 0.89 | SLC6A2 (0.81) | SLC6A2MMP12MMP13 | |
| SCHEMBL11898857 | 0.88 | SLC6A2 (0.79) | SLC6A2MMP12MMP13 | |
| SCHEMBL5740 | 0.86 | SLC6A2 (0.76) | SLC6A2MMP12MMP13 | |
| SCHEMBL11045 | 0.86 | SLC6A2 (0.75) | SLC6A2MMP12MMP13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140364398-A1 | C-Linked Hydroxamic Acid Derivatives Useful As Antibacterial Agents | PFIZER INC. (US) | 2014-12-11 | — | — | US | claimed |
| US-8853258-B2 | C-linked hydroxamic acid derivatives useful as antibacterial agents | PFIZER INC. (US) | 2014-10-07 | — | — | US | claimed |
| US-20120202777-A1 | C-Linked Hydroxamic Acid Derivatives Useful As Antibacterial Agents | BROWN MATTHEW FRANK (US) | 2012-08-09 | — | — | US | claimed |
| US-20260115279-A1 | Methods for Isolation of Lipid-Disc Compositions and Uses Thereof | VIB VZW (BE) | 2026-04-30 | — | — | US | disclosed |
| EP-4396206-A1 | METHODS FOR ISOLATION OF LIPID-DISC COMPOSITIONS AND USES THEREOF | VIB VZW (BE) | 2024-07-10 | — | — | EP | disclosed |
| WO-2023031205-A1 | METHODS FOR ISOLATION OF LIPID-DISC COMPOSITIONS AND USES THEREOF | VIB VZW (BE) | 2023-03-09 | — | — | WO | disclosed |
| US-20140364398-A1 | C-Linked Hydroxamic Acid Derivatives Useful As Antibacterial Agents | PFIZER INC. (US) | 2014-12-11 | — | — | US | disclosed |
| US-20140364398-A1 | C-Linked Hydroxamic Acid Derivatives Useful As Antibacterial Agents | PFIZER INC. (US) | 2014-12-11 | — | — | US | disclosed |
| US-8853258-B2 | C-linked hydroxamic acid derivatives useful as antibacterial agents | PFIZER INC. (US) | 2014-10-07 | — | — | US | disclosed |
| US-8853258-B2 | C-linked hydroxamic acid derivatives useful as antibacterial agents | PFIZER INC. (US) | 2014-10-07 | — | — | US | disclosed |
| EP-2488489-A2 | C-LINKED HYDROXAMIC ACID DERIVATIVES USEFUL AS ANTIBACTERIAL AGENTS | Pfizer Inc. (US) | 2012-08-22 | — | — | EP | disclosed |
| US-20120202777-A1 | C-Linked Hydroxamic Acid Derivatives Useful As Antibacterial Agents | BROWN MATTHEW FRANK (US) | 2012-08-09 | — | — | US | disclosed |
| US-20120202819-A1 | COMBINATION THERAPY USING A BETA 3 ADRENERGIC RECEPTOR AGONISTS AND AN ANTIMUSCARINIC AGENT | MERCK SHARP & DOHME CORPORATION (US) | 2012-08-09 | — | — | US | disclosed |
| WO-2011045703-A2 | C-LINKED HYDROXAMIC ACID DERIVATIVES USEFUL AS ANTIBACTERIAL AGENTS | PFIZER INC. (US) | 2011-04-21 | — | — | WO | disclosed |
| WO-2011045703-A2 | C-LINKED HYDROXAMIC ACID DERIVATIVES USEFUL AS ANTIBACTERIAL AGENTS | PFIZER INC. (US) | 2011-04-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120202777-A1 | C-Linked Hydroxamic Acid Derivatives Useful As Antibacterial Agents | HAX1, LPXN, AGXT | SLC6A2 4624/4885MMP12 482/4885MMP13 549/4885 |
| US-20120202819-A1 | COMBINATION THERAPY USING A BETA 3 ADRENERGIC RECEPTOR AGONISTS AND AN ANTIMUSCARINIC AGENT | ADRB2, ADRB3, ADRA2A | SLC6A2 103/4885MMP12 1416/4885MMP13 1835/4885 |
| US-20260115279-A1 | Methods for Isolation of Lipid-Disc Compositions and Uses Thereof | STT3B, DDOST, PLTP | SLC6A2 2960/4885MMP12 2395/4885MMP13 4226/4885 |
| US-20140364398-A1 | C-Linked Hydroxamic Acid Derivatives Useful As Antibacterial Agents | LCT, AGXT, PRXL2A | SLC6A2 4292/4885MMP12 138/4885MMP13 332/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.